- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07449702
Et åbent udvidelsesstudie af ORKA-001 hos deltagere med plaque psoriasis
Et åbent udvidelsesstudie til evaluering af den langsigtede sikkerhed, tolerabilitet og effektivitet af ORKA-001 hos deltagere med moderat til svær plaque-psoriasis
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Studieoversigt
Detaljeret beskrivelse
This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Oruka Clinical Trials Information
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T5J 3S9
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Edmonton, Alberta, Canada, T6G 1C3
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Surrey, British Columbia, Canada, V3V 0C6
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B IG9
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Ontario
-
Ajax, Ontario, Canada, L1S7K8
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
London, Ontario, Canada, N6H 5L5
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Markham, Ontario, Canada, L3P 1X3
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Peterborough, Ontario, Canada, K9J 5K2
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Toronto, Ontario, Canada, M4W 2N4
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Waterloo, Ontario, Canada, N2J 1C4
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Quebec
-
Montreal, Quebec, Canada, H2X2V1
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Québec, Quebec, Canada, G1V4X7
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85032
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Arkansas
-
North Little Rock, Arkansas, Forenede Stater, 72117
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
California
-
Fountain Valley, California, Forenede Stater, 92708
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Los Angeles, California, Forenede Stater, 90045
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
San Diego, California, Forenede Stater, 92123
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Santa Ana, California, Forenede Stater, 92701
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Santa Monica, California, Forenede Stater, 90403
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Connecticut
-
Cromwell, Connecticut, Forenede Stater, 06416
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Florida
-
Miami, Florida, Forenede Stater, 33126
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Illinois
-
Rolling Meadows, Illinois, Forenede Stater, 60008
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Indiana
-
Plainfield, Indiana, Forenede Stater, 46168
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Kentucky
-
Bowling Green, Kentucky, Forenede Stater, 42104
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- E-mail: clinicaltrials@orukatx.com
-
-
Maryland
-
Rockville, Maryland, Forenede Stater, 20850
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
New York
-
New York, New York, Forenede Stater, 10023
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Mason, Ohio, Forenede Stater, 45040
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97201
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Portland, Oregon, Forenede Stater, 97210
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Texas
-
Frisco, Texas, Forenede Stater, 75033
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Houston, Texas, Forenede Stater, 77004
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Webster, Texas, Forenede Stater, 77598
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23502
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Kontakt:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Signed informed consent by participants from previous trial choosing to transition into the OLE.
- Participants who have successfully completed the preceding trial.
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
Exclusion Criteria:
- Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
- Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
- Participant is pregnant or breastfeeding.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ORKA-001 Once Yearly (High Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Eksperimentel: ORKA-001 Once Yearly (Low Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Eksperimentel: ORKA-001 Twice Yearly
Participants will receive ORKA-001 every 6 months per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Ingen indgriben: No Drug
Participants will receive no drug until protocol defined PASI response criterion is met. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Tidsramme: Day 1 through Week 144
|
Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms. |
Day 1 through Week 144
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Time Frame: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Time Frame: Day 1 through Week 96
|
|
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Tidsramme: Day 1 through Week 96
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
PASI Score Over Time
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
IGA Score Over Time
Tidsramme: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- ORKA-001-113
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .